Joseph Woodard
Net worth: 4 142 $ as of 31/08/2026
Net worth: 4 142 $ as of 31/08/2026
Joseph Paul Woodard formerly worked at Bellicum Pharmaceuticals, Inc., as Senior Vice President-Clinical & Medical Affairs in 2019, Imugene Ltd., as Chief Medical Officer from 2023 to 2025, and Immune-Onc Therapeutics, Inc., as Chief Medical Officer & Senior Vice President.
Dr. Woodard received his undergraduate degree from The University of North Carolina at Charlotte and doctorate degree from UNC School of Medicine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMUGENE LTD 0.02% | 30/06/2025 | 85,007 ( 0.02% ) | 4 142 $ | 31/08/2026 |
| Companies | Position | End |
|---|---|---|
| IMUGENE LIMITED | Chief Tech/Sci/R&D Officer | 30/05/2025 |
| BELLICUM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/11/2019 |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Chief Tech/Sci/R&D Officer | - |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel cellular immunotherapies for various forms of cancer | Health Technology |
Imugene Ltd.
Imugene Ltd. BiotechnologyHealth Technology Operates as a a clinical stage immuno-oncology company | Health Technology |
The University of North Carolina at Charlotte
The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UNC School of Medicine
UNC School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Immune-Onc Therapeutics, Inc.
Immune-Onc Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells | Health Technology |
Select your edition
All financial news and data tailored to specific country editions